Safety and Pharmacokinetic Characteristics of DKF-313

  • STATUS
    Not Recruiting
  • participants needed
    54
  • sponsor
    Dongkook Pharmaceutical Co., Ltd.
Updated on 11 July 2021
dutasteride
tadalafil
avodart

Summary

This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and tadalafil) in healthy male volunteers.

Description

This study is conducted to evaluate the pharmacokinetics of DKF-313 (dutasteride and tadalafil) comparing with the concomitant administration of AVODART and CIALIS in healthy male volunteers.

Details
Condition Benign Prostate Hyperplasia, Healthy
Treatment DKF-313, AVODART, CIALIS
Clinical Study IdentifierNCT02352311
SponsorDongkook Pharmaceutical Co., Ltd.
Last Modified on11 July 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note